{"id":"W4407699987","doi":"10.1200/jco.2025.43.5_suppl.459","title":"Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Nivolumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Immune checkpoint; PD-L1; Ipilimumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005367525,0.0007361619,0.001416698,0.0005503461,0.0002627263,0.0009498174,0.00055027,0.0008088941,0.002254252],"category_scores_gemma":[0.003695809,0.0002520192,0.00598886,0.0006260375,0.00036275,0.0008708631,0.000581669,0.002136605,0.0003044136],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008239759,"about_ca_system_score_gemma":0.0005338612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006247852,"about_ca_topic_score_gemma":0.001274094,"domain_scores_codex":[0.9978861,0.001161761,0.0001789549,0.0002650399,0.0003275467,0.0001806404],"domain_scores_gemma":[0.9966234,0.0009538256,0.001555356,0.0001055704,0.0001721318,0.0005897571],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6166728,0.003915655,0.2377935,0.003869343,0.03486453,0.0001400295,0.0002433093,0.0058666,0.002463249,0.0004121125,0.005570425,0.08818845],"study_design_scores_gemma":[0.08612727,0.1541147,0.7160625,0.0006761338,0.02695419,0.0005041146,0.000329736,0.007459361,0.001821492,0.0008306568,0.004960701,0.0001591948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9801718,0.01133694,0.0004259625,0.0004455625,0.0001778998,0.0003611874,0.005241462,0.0000393903,0.001799682],"genre_scores_gemma":[0.9932854,0.001462206,0.0003554337,0.0003259939,0.00009731782,0.0003964929,0.003597597,0.000007910053,0.0004716721],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005367525,"threshold_uncertainty_score":0.02838659,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05385747611152709,"score_gpt":0.3980470898107144,"score_spread":0.3441896136991873,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}